Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Page 1
Interleukin-10 enhances recruitment of immune cells in the neonatal mouse model of obstructive nephropathy.
Wyczanska M, Thalmeier F, Keller U, Klaus R, Narasimhan H, Ji X, Schraml BU, Wackerbarth LM, Lange-Sperandio B. Wyczanska M, et al. Among authors: keller u. Sci Rep. 2024 Mar 6;14(1):5495. doi: 10.1038/s41598-024-55469-9. Sci Rep. 2024. PMID: 38448513 Free PMC article.
Surprisingly and in contrast to adult Il-10(-/-) mice undergoing UUO, neonatal Il-10(-/-) mice with UUO showed a reduced inflammatory response compared to respective WT control mice with UUO. Notably, long term changes such as renal fibrosis were not different between neon …
Surprisingly and in contrast to adult Il-10(-/-) mice undergoing UUO, neonatal Il-10(-/-) mice with UUO showed a reduced inflammatory respon …
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA. Fuchs M, et al. Among authors: keller ub. Leukemia. 2024 Jan;38(1):160-167. doi: 10.1038/s41375-023-02064-y. Epub 2023 Oct 16. Leukemia. 2024. PMID: 37845285 Free PMC article. Clinical Trial.
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 …
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in p …
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Ferreri AJM, et al. Among authors: keller u. Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13. Leukemia. 2022. PMID: 35562406 Clinical Trial.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess G, Hüttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G. Hess G, et al. Among authors: keller u. Br J Haematol. 2022 Aug;198(3):482-491. doi: 10.1111/bjh.18161. Epub 2022 Apr 1. Br J Haematol. 2022. PMID: 35362552 Clinical Trial.
In summary, pixantrone-obinutuzumab showed clinical activity with sometimes long-term remission; however, the trial failed to meet its primary end-point....
In summary, pixantrone-obinutuzumab showed clinical activity with sometimes long-term remission; however, the trial failed to meet it …
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger K, De Filippi R, Lindén O, Viardot A, Hess G, Lerch K, Neumeister P, Stroux A, Peuker CA, Pezzutto A, Pinto A, Keller U, Scholz CW. Rieger K, et al. Among authors: keller u. Ann Hematol. 2022 Apr;101(4):781-788. doi: 10.1007/s00277-022-04781-3. Epub 2022 Feb 12. Ann Hematol. 2022. PMID: 35150296 Free PMC article.
Radioimmunotherapy with 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment in patients with follicular lymphoma (FL) demonstrated promising results with a complete remission (CR) rate of 56% and a median progression-free survival (PFS) of 26 months, when initially a …
Radioimmunotherapy with 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment in patients with follicular lymphoma (FL) demonstra …
Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort.
Lackamp N, Wilkemeyer I, Jelas I, Keller U, Bullinger L, Stintzing S, le Coutre P. Lackamp N, et al. Among authors: keller u. Front Oncol. 2021 Nov 5;11:772809. doi: 10.3389/fonc.2021.772809. eCollection 2021. Front Oncol. 2021. PMID: 34804976 Free PMC article.
Progress in oncological treatment has led to an improved long-term survival of young male cancer patients over the last decades. ...Cryopreservation of sperm is the current standard option to preserve patient's fertility after treatment, yet long-term data on usage …
Progress in oncological treatment has led to an improved long-term survival of young male cancer patients over the last decades. ...C …
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker S, Bittner A, Frick M, Kase J, Hoffmann J, Trenker C, Keller U, Bogner C, Hüttmann A, Dürig J, Janz M, Mathas S, Marks R, Krohn U, Na IK, Bullinger L, Schmitt CA. Denker S, et al. Among authors: keller u. Leuk Lymphoma. 2022 Jan;63(1):84-92. doi: 10.1080/10428194.2021.1964024. Epub 2021 Aug 20. Leuk Lymphoma. 2022. PMID: 34414850
Enhancing first-line efficacy in patients at higher risk, among them many elderly, is key to improve long-term outcomes. Numerous attempts to combine R-CHOP with targeted agents failed in large randomized phase III trials. ...
Enhancing first-line efficacy in patients at higher risk, among them many elderly, is key to improve long-term outcomes. Numerous att …
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P; German Hodgkin Study Group. Kreissl S, et al. Among authors: keller ub. Lancet Haematol. 2021 Jun;8(6):e398-e409. doi: 10.1016/S2352-3026(21)00101-0. Lancet Haematol. 2021. PMID: 34048679 Clinical Trial.
In the subgroup of PET-2-negative patients randomly assigned after protocol amendment, 5-year progression-free survival was 90.9% (95% CI 86.8 to 95.1) in 202 patients assigned to receive six cycles of eBEACOPP and 91.0% (86.6 to 95.5) in 200 patients assigned to receive four cyc …
In the subgroup of PET-2-negative patients randomly assigned after protocol amendment, 5-year progression-free survival was 90.9% (95% CI 86 …
ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity.
Pohl J, Mincu RI, Mrotzek SM, Wakili R, Mahabadi AA, Potthoff SK, Siveke JT, Keller U, Landmesser U, Rassaf T, Anker MS, Totzeck M. Pohl J, et al. Among authors: keller u. Cancers (Basel). 2021 Mar 10;13(6):1197. doi: 10.3390/cancers13061197. Cancers (Basel). 2021. PMID: 33801913 Free PMC article.
METHODS: We performed a retrospective analysis of 134 therapy-naive consecutive cancer patients in our two university hospitals concerning four ECG score parameters: Contiguous Q-waves, markers of left ventricular (LV) hypertrophy, QRS duration and JTc prolongation. Cardiotoxicit …
METHODS: We performed a retrospective analysis of 134 therapy-naive consecutive cancer patients in our two university hospitals concerning f …
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Among authors: keller u. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. Lancet Oncol. 2021. PMID: 33539742 Clinical Trial.
BACKGROUND: Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. However, the use of radiotherapy can have long-term sequelae, which is of particular concern, …
BACKGROUND: Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care for patients with earl …
44 results